Gilead Sciences Inc GIS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GIS is a good fit for your portfolio.
News
-
Gilead's quarterly loss is narrower than expected
-
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
-
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration
-
Xilio Shares Take Flight Premarket After Gilead Deal
-
Gilead Says FDA Expands Approval of Chronic Hep-B Infection Treatment for Use in Kids
-
Xilio Therapeutics Plans Private Placement, Job Cuts
-
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program
-
Gilead, Merck Report Positive Phase 2 Data on Weekly Oral HIV Combo
Trading Information
- Previous Close Price
- $59.60
- Day Range
- $58.03–60.85
- 52-Week Range
- $46.23–—
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $75.81 Bil
- Volume/Avg
- 1,136 / 1,029
Key Statistics
- Price/Earnings (Normalized)
- 16.38
- Price/Sales
- 3.02
- Dividend Yield (Trailing)
- 4.63%
- Dividend Yield (Forward)
- 4.72%
- Total Yield
- 5.51%
Company Profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 18,000
- Website
- https://www.gilead.com
Competitors
Valuation
|
Metric
|
GIS
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.38 | 59.67 | 10.03 |
Price/Book Value | 4.67 | 8.12 | 4.74 |
Price/Sales | 3.02 | 5.37 | 2.17 |
Price/Cash Flow | 7.74 | 18.88 | 9.81 |
Price/Earnings
GIS
MRK
GSK
Financial Strength
|
Metric
|
GIS
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.72 | 0.68 | 0.57 |
Current Ratio | 1.08 | 1.25 | 0.87 |
Interest Coverage | 2.11 | 3.97 | 8.94 |
Quick Ratio
GIS
MRK
GSK
Profitability
|
Metric
|
GIS
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 8.33% | 5.22% | 11.25% |
Return on Equity (Normalized) | 24.25% | 13.56% | 51.21% |
Return on Invested Capital (Normalized) | 12.71% | 8.29% | 22.40% |
Return on Assets
GIS
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Nvpwwpcky | Npgp | $834.9 Bil | |||
| Johnson & Johnson
JNJ
| Vylsscx | Wgr | $350.3 Bil | |||
| Merck & Co Inc
MRK
| Xlpnclt | Vlj | $327.9 Bil | |||
| AbbVie Inc
ABBV
| Ncljwqb | Lqd | $297.7 Bil | |||
| AstraZeneca PLC ADR
AZN
| Jwshqrlhqr | Brmc | $247.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Flkqdjmv | Bsgzr | $223.9 Bil | |||
| Novartis AG ADR
NVS
| Wcsgvbf | Zfmcb | $216.8 Bil | |||
| Amgen Inc
AMGN
| Vmpgjtwtw | Splzn | $160.2 Bil | |||
| Pfizer Inc
PFE
| Vpwvyxb | Jmpf | $156.0 Bil | |||
| Sanofi SA ADR
SNY
| Jctfsxvv | Rnx | $116.1 Bil |